Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Current Liabilities (2016 - 2025)

Gsk has reported Total Current Liabilities over the past 10 years, most recently at $28.5 billion for Q4 2025.

  • Quarterly results put Total Current Liabilities at $28.5 billion for Q4 2025, up 2.17% from a year ago — trailing twelve months through Dec 2025 was $28.5 billion (up 2.17% YoY), and the annual figure for FY2025 was $28.5 billion, up 2.17%.
  • Total Current Liabilities for Q4 2025 was $28.5 billion at Gsk, up from $27.8 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for GLAXF hit a ceiling of $31.9 billion in Q4 2021 and a floor of $26.1 billion in Q4 2023.
  • Median Total Current Liabilities over the past 5 years was $27.8 billion (2024), compared with a mean of $28.2 billion.
  • Biggest five-year swings in Total Current Liabilities: grew 9.1% in 2021 and later dropped 16.15% in 2022.
  • Gsk's Total Current Liabilities stood at $31.9 billion in 2021, then decreased by 16.15% to $26.8 billion in 2022, then fell by 2.26% to $26.1 billion in 2023, then increased by 6.5% to $27.8 billion in 2024, then rose by 2.17% to $28.5 billion in 2025.
  • The last three reported values for Total Current Liabilities were $28.5 billion (Q4 2025), $27.8 billion (Q4 2024), and $26.1 billion (Q4 2023) per Business Quant data.